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Abstract
There is an urgent need to develop safer and more effective drugs for Chagas disease, as the current treatment relies on
benznidazole (BZ) and nifurtimox (NFX). Using the Trypanosoma cruzi Dm28c strain genetically engineered to express
the Escherichia coli b-galactosidase gene, lacZ, we have adapted and validated an easy, quick and reliable in vitro assay
suitable for high-throughput screening for candidate compounds with anti-T. cruzi activity. In vitro studies were
conducted to determine trypomastigotes sensitivity to BZ and NFX from Dm28c/pLacZ strain by comparing the
conventional labour-intensive microscopy counting method with the colourimetric assay. Drug concentrations producing the lysis of 50% of trypomastigotes (lytic concentration 50%) were 41.36 and 17.99 mM for BZ and NFX, respectively,
when measured by microscopy and 44.74 and 38.94 mM, for the colourimetric method, respectively. The optimal
conditions for the amastigote development inhibitory assay were established considering the parasite–host relationship (i.e. multiplicity of infection) and interaction time, the time for colourimetric readout and the incubation time with
the b-galactosidase substrate. The drug concentrations resulting in 50% amastigote development inhibition obtained
with the colourimetric assay were 2.31 mM for BZ and 0.97 mM for NFX, similar to the reported values for the Dm28c wild

Received: 10 November 2020; Revised: 15 March 2021; Editorial Decision: 16 March 2021; Accepted: 1 July 2021
C The Author(s) 2021. Published by Oxford University Press.
V

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com

1

Downloaded from https://academic.oup.com/biomethods/article/6/1/bpab004/6321447 by guest on 08 August 2022

Optimization and biological validation of an in vitro
assay using the transfected Dm28c/pLacZ Trypanosoma
cruzi strain

2

| Gulin et al.

strain (2.80 and 1.5 mM, respectively). In summary, a colourimetric assay using the Dm28c/pLacZ strain of T. cruzi has
been set up, obtaining biologically meaningful sensibility values with the reference compounds on both trypomastigotes and amastigotes forms. This development could be applied to high-throughput screening programmes aiming
to identify compounds with anti-T. cruzi in vitro activity.
Keywords: Trypanosoma cruzi; in vitro drug screening; high-throughput screening

Introduction

Materials and methods
Test compounds and reagents
To set the new assay up, the drugs currently marketed for the
chemotherapy of Chagas disease were selected as reference

R

R

R

Parasite and cell culture
Trypanosoma cruzi Dm28c epimastigotes were cultured at 28 C in
LIT medium (5 g/l liver infusion, 5 g/l bacto-tryptose, 68 mM
NaCl, 5.3 mM KCl, 22 mM Na2HPO4, 0.2% (w/v) glucose and
0.002% (w/v) hemin supplemented with 10% (v/v) FBS.
Vero C-76 cell line [purchased in the American Type Culture
Collection (ATCC) certified Asociación Banco Argentino de
Células] (passages 32–42) and monolayers for obtaining T. cruzi
cell-culture derived trypomastigotes were maintained at 37 C
and 5% CO2. Trypomastigotes were harvested according to a
published protocol [17]. Cultures to be assayed for b-galactosidase activity were grown in RPMI-1640 medium without phenol
red supplemented with 2.5 g/l sodium bicarbonate, 5% FBS and
a periodical antibiotic switching (100 UI/ml of penicillin and 50
mg/ml of streptomycin or 25 mg/ml of gentamicin).

Transfection assay
The Dm28c/pLacZ strain of T. cruzi was generated from a plasmid generously provided by Dr Frederick S. Buckner [14]. Briefly,
epimastigotes were cultured in LIT medium at 28 C to a final
concentration of 4  107 parasites per transfection. Then, parasites were harvested by centrifugation at 1500g for 10 min at
room temperature, washed once with phosphate-buffered
saline (PBS) and resuspended in 0.4 ml BSF transfection buffer (5
mM KCl, 0.15 mM CaCl2 90 mM, Na2HPO4 50 mM HEPES pH 7.3).
Nucleofection (Nucleofector 2B, Lonza) was performed in a 0.2
cm gap cuvette (Bio-Rad) with 20 mg of pLacZ plasmid DNA
added to a final volume of 400 ml. The parasite–DNA mixture
was kept on ice for 20 min prior to nucleofection with programme X-014. After nucleofection, cells were transferred into 3
ml of LIT medium containing 20% FBS, maintained at room temperature for 15 min and then incubated at 28 C. Geneticin was
added at a concentration of 200 mg/ml, and parasites were incubated at 28 C. Transgenic parasites were obtained after 4 weeks
of selection.
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American trypanosomiasis (Chagas disease) is an endemic
disease in Latin America caused by the haemoflagellate protozoa Trypanosoma cruzi that affects 6–7 million people worldwide [1].
The complex life cycle of T. cruzi involves over 150 mammalian hosts and triatomine blood-sucking bugs. Typically, vectorial transmission occurs when infected bug faeces contaminate
the bite site or through intact mucous membranes. Oral infection is usually linked with the ingestion of food and/or drinks
with infected triatomine faeces [2].
Non-vectorial routes of infection include blood transfusions
or organ transplants with non-tested donors, laboratory accidents and vertical transmission by transplacental passage,
which is currently responsible for most new cases in urban
areas [3]. Chagas disease is becoming and emergent health burden in non-endemic regions due to the migrant population and
non-vectorial transmission routes [4].
Current treatment options for Chagas disease are limited to
nifurtimox (NFX) and benznidazole (BZ), developed in 1966 and
1970, respectively [5]. While the efficacy of both drugs in the
acute stage of infection is clearly demonstrated, etiological
treatment during the chronic phase remains in dispute, according to recent clinical trials [6, 7]. Additionally, the long duration
of therapy (i.e. 60 days) and severe frequent side effects often
hamper treatment adherence [8]. In this context, there is an urgent need to identify new and better options to improve Chagas
disease chemotherapy.
In vitro drug screening efforts have primarily involved
labour-intensive microscopy counting of parasites to determine
compound activity [9]. More recently, several biotechnology
tools were applied to accelerate in vitro evaluation of new compounds, such as high-throughput [10, 11] or high-content
screening [12, 13].
The establishment of a T. cruzi transfected strain with the
Escherichia coli b-galactosidase gene (lacZ) was first developed by
Buckner et al. [14]. In this model, the C4 clone of the Tulahuen
strain and the B5 clone of the CL strain [both from discrete typing unit (DTU) VI] express an enzyme that hydrolyses the chromogenic substrate chlorophenol-red-b-D-galactopyranoside
(CPRG) to chlorophenol red, catalyzing a colourimetric reaction
[15].
In this work, we describe the development, optimization and
biological validation of an in vitro assay using a b-galactosidasetransfected Dm28c T. cruzi strain (DTU I) for colourimetric
high-throughput screening system to assess the efficacy on
both trypomastigotes and intracellular amastigotes.

compounds: BZ and NFX. Pure drugs were provided by Roche,
Brazil, Bayer and Germany, respectively, and they were dissolved in dimethyl sulfoxide (DMSO; StantonV, Buenos Aires,
Argentina) in stock solutions at 20 mg/ml. DMSO concentration
never exceeded 0.2% in plate wells, with no effect on the host
cell viability nor parasite replicative growth [16]. Roswell Park
Memorial Institute (RPMI)-1640 with or without phenol red
(Sigma; R6504 or R8755, respectively). Sodium bicarbonate
(EmeveV; P1551-500). Gentamicin (Sigma; G1397). Penicillin–
streptomycin (Sigma; P4333). Resazurin solution (Sigma, R7017).
CPRG (Roche Diagnostics GmbH; 10 884 308 001). NonidetTM P-40
substitute (Roche Diagnostics GmbH; 11 754 599 001). Heatinactivated, UV-irradiated foetal bovine serum (FBS) (NatocorV
or Internegocios S.A, Argentina). Geneticin (G418; Life
Technologies).

Optimization and biological validation of an in vitro assay

b-galactosidase activity assay

R

Trypomastigote lysis assay
Cell-cultured derived trypomastigotes (1  105 parasites) were
plated in 50 ml RPMI-1640 without phenol red and 10% FBS and
incubated with 4-fold serially diluted concentrations of BZ or
NFX (160–0.039 mM) at 37 C and 5% CO2 for 24 h in 96-well tissue
culture plates (NestV; 701001) in 100 ml as final volume. Then, 50
ml of a CPRG solution (100 mM final concentration) was added to
each well and incubated at 37 C in an atmosphere of 5% CO2 for
4 h. The b-galactosidase activity was quantitated at 570 nm in
an ELISA reader. Each drug concentration was evaluated by triplicate, and non-treated trypomastigotes were included as a
control.
An identical assay was carried out in parallel, and the final
readout was determined by counting the motile trypomastigotes in KOVA Glasstic slidesV in optic microscopy. There were
performed three independents replicates for both assays.
The lytic concentration 50% (LC50), defined as the drug concentration that resulted in a 50% reduction of motile trypomastigotes compared with the untreated control, was estimated by
non-linear regression analysis [18].
R

R

Amastigote development inhibition assay
R

Ninety-six-well tissue culture plates (NestV; 701001) were
seeded with Vero C-76 cell line at 104 per well in 100 ml of RPMI1640 and 5% FBS and incubated overnight at 37 C and 5% CO2.
Then, wells were rinsed with sterile PBS 1X, and T. cruzi Dm28c
strain b-galactosidase-expressing trypomastigotes were added
in a multiplicity of infection (MOI) equal to 1, 5 or 10 per well in
100 ml of RPMI-1640 and 5% FBS. After 2, 6 and 24 h of interaction, plates were washed, and treatment was added in 200 ml of
RPMI-1640 and 5% FBS.
At 3, 4 or 5 days post-infection (dpi), when expanded numbers of trypomastigotes were easily visible in control wells, the
plates were washed with sterile PBS 1X and filled with 100 ml
of RPMI-1640 without phenol red, CPRG (100 mM final concentration) and Nonidet P-40 (0.1% final concentration). Plates were
incubated for 2, 4, 6 or 24 h at 37 C and 5% CO2. The b-galactosidase activity was quantitated at 570 nm in an ELISA reader.
BZ was added to infected plates at 10 mM and incubated
during the different times, as stated above. After the assay conditions were selected, drug compounds were added in serial dilutions in 200 ml of RPMI-1640 and 5% FBS. Each drug concentration
was evaluated by triplicate, and infected non-treated and noninfected non-treated cells were included in each replicate.
The non-parametric Kolmogorov–Smirnov test allowed the
establishment of optimal assay conditions, detecting the differences between the non-treated wells and BZ treatment (10 mM)
by providing the D value. The null hypothesis was that both

3

groups were sampled from populations with identical distributions. Geometrically, the D value measures the maximum vertical distance between the empirical cumulative distribution
function (ECDF) of the sample and the cumulative distribution
function of the reference distribution. Thus, D ranges between 0
and 1, where 0 occurs if the two ECDFs are identical and 1 if the
two samples are completely distinct [19].

Cell toxicity
To assess the drug toxicity on the Vero C-76 cell line, 104 cells/
well were seeded in 96-well plates and incubated overnight at
37 C in an atmosphere of 5% CO2. Then, wells were rinsed and
incubated in the presence of BZ or NFX at 4-fold serially diluted
concentrations (160–0.156 mM). After 5 days, plates were
washed, and 100 ml of RPMI þ 5% FBS and 10% of a 3 mM resazurin solution were added to each well. The plates were incubated at 37 C with a 5% CO2 atmosphere for 4 h and read at 570–
595 nm in an ELISA reader (MultiskanEX, Thermo ScientificV) to
obtain a dose–response curve [20]. Each drug concentration was
evaluated by triplicate, and non-treated cells were included in
each replicate. The cytotoxic concentration 50 (CC50), defined as
the concentration of compound capable of damaging 50% of
the cells, was calculated using GraphPad Software, San Diego,
CA, USA (www.graphpad.com).
R

Results
b-galactosidase activity assay
Figure 1 shows the relationship between the coloured product
and the concentration of cell culture-derived trypomastigotes
plated in each well. The b-galactosidase activity increased proportionally with parasite concentration. The best curve fitting
was achieved when trypomastigotes were incubated with the
substrate solution for 4 h (R2 ¼ 0.9816), and b-galactosidase activity was linear in the range of 3 150–100 000 trypomastigotes per
well (i.e. 31 500–1 000 000 trypomastigotes/ml). An illustrative
culture plate is included as Supplementary material (Fig. S1).

Trypomastigote lysis assay
The in vitro activity of NFX and BZ on trypomastigotes of
Dm28c/pLacZ strain from T. cruzi was assessed with the previously established colourimetric method, and the LC50 values
were compared with the LC50 obtained by direct microscopic
counting (Table 1 and Fig. 2).

Figure 1: b-galactosidase activity (OD at 570 nm) with different concentrations of
cell-culture derived trypomastigotes from Dm28c/pLacZ strain of T. cruzi after
incubation at 37 C and 5% of CO2 at different time points. Each value represents
the mean and the standard deviation of three independent replicates. The dark
continuous line represents the curve fit.
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To assess whether the b-galactosidase activity was associated
with parasite burden, 2  105 cell-cultured derived b-galactosidase-expressing trypomastigotes from Dm28c/pLacZ strain of
T. cruzi were seeded in 90 ml RPMI-1640 medium without phenol
red and supplemented with 5% FBS per well. Two-fold serial
dilutions were plated in each well, and then 10 ml of cell culture
medium containing substrate solution (CPRG and Nonidet P-40,
at 100 mM and 0.1% of final concentration, respectively) was
added. After incubation with CPRG at 2, 4, 6 and 24 h at 37 C and
5% CO2, the plates were read in an Enzyme-Linked
ImmunoSorbent Assay (ELISA) reader at 570 nm (Multiskan EX,
Thermo ScientificV).
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Table 1: In vitro activity of benznidazole and nifurtimox on trypomastigotes of Dm28c/pLacZ strain of Trypanosoma cruzi, obtained with direct
microscopic counting or with the colorimetric method.
Compound

Direct microscopic counting
LC50 (95% CI)

BZ
NFX

41.36
(35.50; 48.18)
17.99
(12.32; 26.26)

R2

R2

Colourimetric method
LC50 (95% CI)

0.98
0.90

44.74
(40.93; 48.91)
38.94
(37.05; 40.92)

0.99
0.99

Mean values (95% CI) are expressed in mM.

on the Dm28c/pLacZ strain of T. cruzi trypomastigotes. Each value represents the mean and the standard deviation of three independent replicates. The dark continuous line represents the curve fit. Dotted lines indicate 50 and 90% trypomastigote lysis. References: (C) BZ: A1-C1: 160 mM; A2-C2: 40 mM; A3-C3: 10 mM; A4-C4: 2.5 mM;
A5-C5: 0.625 mM; A6-C6: 0.156 mM; A7-C7: NT (non-treated). (D) NFX: A1-C1: 160 mM; A2-C2: 40 mM; A3-C3: 10 mM; A4-C4: 2.5 mM; A5-C5: 0.625 mM; A6-C6: NT (non-treated).

Table 1 shows the LC5 values for NFX and BZ obtained both
by the direct microscopic counting and colourimetric methods.
A correlation higher than 0.9 and narrow confidence intervals
(CIs) were obtained for both screening methods. Regarding BZ,
the obtained LC50 values were similar with both methods.
However, the LC50 value for NFX obtained with the microscopic
counting method nearly doubled the LC50 value calculated with
the colourimetric method.

Amastigote development inhibition colourimetric assay
optimization
We have studied 27 possible combinations, among the different
conditions: parasite–cell relationship (MOI ¼ 1, 5 or 10); time for
parasite–cell interaction (2, 6, 24 h), amastigote development
(3, 4 or 5 dpi) and incubation time (2, 4, 6 or 24 h). The nonparametric Kolmogorov–Smirnov test allowed to establish the
optimal conditions in which the differences were significantly
greater comparing treated (BZ, 10 mM) and non-treated wells.
Table 2 and Fig. 3 indicate the experimental conditions with the

Table 2: Experimental conditions for the colorimetric assay with the
Dm28c/pLacZ strain of Trypanosoma. cruzi.
Experimental conditions

Combination 2
Combination 3
Combination 4
Combination 5
Combination 11

MOI

Interaction
time

dpi

D value

P-value

1
1
1
1
5

2
2
6
6
2

4
5
3
4
4

0.75
0.83
0.75
0.75
0.75

0.0023
0.0005
0.0023
0.0023
0.0023

D value ranges between 0 and 1, where 0 occurs if the two ECDF are identical
and 1 if the two samples are completely distinct.
P-values <0.05 were considered significant.
MOI: multiplicity of infection.

most significant differences. Results from all tested combinations can be observed in Supplemental Table S1.
To move forward with the high-throughput colourimetric
system optimization, the experimental conditions that
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Figure 2: Concentration–response curves for (A) BZ and (B) NFX and culture plates corresponding to the colourimetric assay to determine (C) BZ LC50 and (D) NFX LC50
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exhibited higher D-value at the shortest interaction time and
less dpi at the time of the substrate incubation were selected.
Accordingly, the optimal assay conditions were established
as follows: Vero C-76 cells (104/well) were seeded in 100 ml of
RPMI þ 10% FBS in 96-well culture plates. After 24 h, wells were
washed with sterile PBS 1X, and cells were infected with
culture-derived trypomastigotes from the Dm28c/pLacZ strain
of T. cruzi, with MOI¼5 and 2 h of interaction. Then, wells
were washed with sterile PBS 1X to remove unbound cells and
parasites. Later, seven serial dilutions (160–0.039 mM) of the reference drugs (i.e. BZ or NFX) in RPMI þ 10% FBS were dispensed
to the infected cells in a final volume of 200 ml per well. Infected

non-treated and non-infected non-treated cells were included
in each replicate. At 4 dpi, wells were washed with sterile PBS
1X, and then cell culture media (RPMI with 5% FBS without phenol red) with substrate solution (CPRG at 100 mM and Nonidet
P-40 at 0.1%, final concentration) was added. The plates were
read in an ELISA reader at 570 nm after 4 h of incubation at 37 C
and 5% CO2.

Amastigote development inhibition assay
The 50% inhibitory concentration (IC50) values for BZ and NFX
for the T. cruzi Dm28c/pLacZ strain obtained with the
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Figure 3: OD versus incubation time (2, 4, 6 and 24 h) with the substrate solution. Average OD values (normalized to 1) are indicated for non-treated wells (continuous
blue line) and wells treated with 10 mM of BZ (dashed blue line).
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Table 3: In vitro activity of benidazole and nifurtimox on intracellular amastigotes development from Dm28c/pLacZ strain of Trypanosoma cruzi.
Compound
BZ
NFX

IC50 (95% CI)

IC90 (95% CI)

R2

2.31
(2.14; 2.49)
0.97
(0.90; 1.05)

8.60
(5.99; 12.30)
3.51
(2.09; 5.69)

CC50 (95% CI)

SI

0.99

>160

>69

0.99

>160

>165

Vero C-76 cells infected with cell-culture derived trypomastigotes from Dm28c/pLacZ strain of T. cruzi in a MOI ¼ 5, 2 h of interaction and 4 days of treatment. SI: selectivity
index. SI¼ CC50/IC50.

ment. A1-C1: 160 mM, A2-C2: 40 mM; A3-C3: 10 mM; A4-C4: 2.5 mM; A5-C5: 0.625 mM; A6-C6: 0.156 mM; D1-D3: 0.039 mM; D4-D6: infected non-treated cells Vero-C76 cells; E1E3: non-infected non-treated Vero-C76 cells; E4: RPMI-1640 þ 5% FBS; E5: RPMI-1640 without phenol red þ 5% FBSþ CPRG 100 mM þ Nonidet P-40, 0.1%; E6: empty well.
(D) Representative plate for the amastigote inhibitory activity assay with NFX treatment. A1-C1: 160 mM, A2-C2: 40 mM; A3-C3: 10 mM; A4-C4: 2.5 mM; A5-C5: 0.625 mM; A6C6: 0.156 mM; D1-D3: 0.039 mM; D4-D6: infected non-treated Vero-C76 cells. D4-D6: infected non-treated cells Vero-C76 cells; E1-E3: non-infected non-treated Vero-C76
cells; E4: RPMI-1640 þ 5% FBS; E5: RPMI-1640 without phenol red þ 5% FBSþ CPRG 100 mM þ Nonidet P-40, 0.1%; E6: empty well.

colourimetric screening method are indicated in Table 3. The
concentration–response curves are shown in Fig. 4.

Discussion
An in vitro colourimetric method was standardized and biologically validated to establish a suitable model for highthroughput drug screening using the Dm28c/pLacZ strain of
T. cruzi.
The T. cruzi Dm28c strain was originally isolated from a common opossum (Didelphys marsupialis) in Carabobo, Venezuela,

and it belongs to the DTU TcI [21]. The Dm28c strain was characterized both in vitro and in vivo [22], and its genome was recently
sequenced [23].
Several T. cruzi strains have been previously genetically
engineered: Tulahuen, CL, Peru, Sonja, VL2067, among others
and are also available at the ATCC [24].
Briefly, the parasites have been genetically modified to express the E. coli lacZ. This enzyme is able to catalyze a reaction
with CPRG as a substrate, and the generated product is directly
proportional to the transfected parasites burden, allowing to
quantify it by colourimetric readers [18].
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Figure 4: Concentration–response curves for (A) BZ and (B) NFX and culture plates corresponding to the colourimetric assay to determine (C) BZ IC50 value and (D) NFX
IC50 value on the Dm28c/pLacZ strain of Trypanosoma cruzi amastigotes. Dotted lines indicate 50 and 90% inhibition of amastigote development. Each value represents
the mean and the standard deviation of three independent replicates. References: (C) Representative plate for the amastigote inhibitory activity assay with BZ treat-
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In summary, this colourimetric assay using the Dm28c/
pLacZ strain of T. cruzi has been set up to improve and
optimize drug screening capacity, obtaining biologically
meaningful values from BZ and NFX sensitivity. This development can be included in a panel of several T. cruzi strains
and applied in a high-throughput screening programme of
large drug libraries to identify compounds with anti-T. cruzi
activity.

Supplementary data
Supplementary data is available at Biology Methods and
Protocols online.
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The MOI (i.e. the parasite:cell infection ratio), the interaction
time and the incubation time with the substrate are some of
the critical steps to establish a successful in vitro infection and
to correctly evaluate the chosen readout to assess the efficacy
of candidate compounds on T. cruzi [25].
The optimal experimental conditions for this assay using
the Dm28c/pLacZ strain (DTU TcI) were similar to the previously
established protocol with CL and Tulahuen strains (DTU TcVI)
[18, 26, 27].
The development of in vitro high-throughput screening platforms with similar experimental conditions and readouts would
allow comparing the obtained results in different strains, thus
explaining the differences in drug sensitivity due to intraspecific variety among the T. cruzi complex. As these differences
were previously documented, high-throughput screening
should consider the T. cruzi strain variability [28].
The optimization of the colourimetric assay to assess the
amastigote development inhibition was tested with BZ since it
is the reference compound for drug screening [29]. Among the
different tested experimental conditions, the protocol that led
to better outcomes was: a MOI¼ 5; 2 h of cell–parasite interaction, readout at 4 dpi and plate reading after 4 h of incubation
with the substrate. Under these conditions, results were
obtained in a total of 5 days of experimental work. Despite the
larger number of trypomastigotes needed per well, the optical
densities differences between treated and untreated wells were
wide, allowing to obtain accurate IC50 values.
Combination II (MOI ¼ 1; 2 h of cell–parasite interaction and
readout at 4 dpi) was not selected despite the statistical support
since MOI ¼ 1 would require a very high infection rate which
may not be achieved in all experiments. Furthermore, combination III (MOI ¼ 1; 2 h of cell–parasite interaction and readout at 5
dpi) was discarded despite its higher D value since experiments
would take longer to obtain results.
Coloured compounds might interfere with readout when using colourimetric readings [30]. To overcome this difficulty in
the amastigote development inhibition assay, we modified the
original protocol from Buckner et al. [14] by removing the supernatant from the wells before adding the substrate in a cell culture medium without phenol red. This intermediate step would
avoid the interference in colourimetric readings due to the absorbance of coloured compounds [24].
Furthermore, this additional step allowed discarding the trypomastigotes that would have emerged from the infected cells,
generating a higher coloured signal and possibly underestimating the compound activity.
For all the transfection process, drug sensitivity from
Dm28c/pLacZ strain remained similar to wild-type strain. The
obtained IC50 values for BZ and NFX on intracellular amastigotes
development were biologically significant, with similar BZ values as reported with the Dm28c wild strain in a high-content
screening method. Likewise, the value obtained for NFX on the
Dm28c/pLacZ strain was slightly lower than BZ and in the same
order of magnitude as reported for the wild Dm28c strain [31].
The effect of the reference drugs on trypomastigotes from
the Dm28c/pLaZ was studied with the colourimetric method
and the microscopic method as well. For BZ, the obtained
LC50 value was very similar between both methods. In
contrast, the obtained LC50 value for NFX with the standard
microscopic counting method was 15 mM less than the colourimetric method. This difference could be explained due
to the naturally coloured of the compound, which could
interfere with the colourimetric reading at similar optical
density (OD).
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